Compass Pathways Shares Add 6% on One-Year COMP360 Data

Compass Pathways said its psilocybin candidate COMP360 produced positive one-year data, and shares of CMPS traded at 14.88, up 5.98% on the day as of 16:29 GMT on Sept. 9, 2026, while newly public Solstice made a $225 million debut.

Compass Pathways (CMPS) said its synthetic psilocybin candidate COMP360 delivered positive results at the one-year mark, and the market took the durability question seriously. The stock traded at 14.88 as of 16:29 GMT on Sept. 9, 2026, up 5.98% from the prior close of 14.04, with an intraday range of 14.05 to 15.35 — a session high that sat well above the open range and then gave part of itself back. That happened on a day when the broad market was lower: the S&P 500 tracker (SPY) was at $761.51, down 0.58%, and the Nasdaq 100 tracker (QQQ) at $714.76, down 0.50%.

The same session brought a $225 million debut for Solstice, a figure that matters to every private biotech currently deciding whether to file or wait. Both items appeared in Endpoints News, alongside items on Luma, Inno Medicine, Schrödinger, Assembly Biosciences, Gilead, Leyden Labs, Navion, Ridge Bio and Opus Genetics.

Why a one-year readout is the readout that counts for psilocybin

Psychedelic medicine has never had trouble producing striking short-term numbers. A single supervised dosing session, measured a few weeks later, has repeatedly looked good on depression rating scales. The commercial and regulatory problem has always been what happens after that — whether the effect holds, how many patients relapse, and whether a second dose is needed and safe.

That is why the word "one-year" is doing the work in Compass's announcement. A durable response at twelve months changes the shape of the product. It moves COMP360 from something that looks like an acute intervention needing repeat administration toward something closer to an episodic treatment, which in turn changes how payers model cost per patient and how clinics model throughput. The lead does not give the individual efficacy figures, and this article will not invent them; what the market response tells you is that investors read the direction as favorable.

The share reaction is worth reading precisely. A move of roughly 6% on positive long-term follow-up data is a respectful gain, not a re-rating. Follow-up data from an existing dataset is confirmatory by nature: it removes a risk rather than adding an asset. The retreat from the 15.35 intraday high to 14.88 by late morning suggests some holders used the news to take a print rather than to build.

Solstice's $225 million and the state of the IPO window

A $225 million debut is not a small deal in any biotech market, and it lands as a signal about capacity. Crossover funds do not put nine figures into a newly public name unless they are willing to hold through at least one clinical event, which implies conviction on the asset and comfort with the exit horizon.

For the private pipeline, the number sets a marker in two directions. It shows the buy side will fund at scale, which encourages boards sitting on filed-but-paused S-1s. It also raises the bar: deals that size tend to concentrate demand, and a fund that has just committed to a $225 million book has less appetite for the next three offerings in the queue. Windows in this sector have historically opened for a handful of assets, not for everybody.

The rest of the tape was not cooperating

Compass's gain came against a broadly negative session across the names in the same news cycle, which is a useful reminder that a single positive readout does not lift a sector.

Schrödinger (SDGR) traded at 19.39, down 3.20% from a prior close of 20.03, having ranged from 19.24 to 20.02 — a session spent almost entirely below the previous close.
Assembly Biosciences (ASMB) was at 33.54, down 4.93% from 35.28, with a wide 33.16 to 35.93 range that points to genuine two-way disagreement rather than drift.
Gilead (GILD) sat at 145.78, off 0.59% from 146.64, a large-cap move essentially in line with the broad indices.
The outlier was IRD at 5.64, up 29.95% from a prior close of 4.34. That stock printed as high as 7.08 before surrendering a substantial part of the gain — the classic shape of a news-driven small-cap where the first buyers pay the top price.

Set against SPY at $761.51 and DIA at $523.81, down 0.80%, the pattern is a soft market where company-specific news is the only thing generating upside. Compass and IRD were doing their own work; Schrödinger and Assembly were being sold harder than the index.

What determines whether the COMP360 gain sticks

80%, the pattern is a soft market where company-specific news is the only thing generating upside.

Durability data answers one question and immediately raises three others. Investors deciding what today's 6% is worth will be watching for a small number of specific things.

The regulatory reading. Long-term follow-up strengthens a filing package, but the pivotal endpoints are what a regulator adjudicates. The one-year data is supporting evidence, not a substitute for it.

The delivery model. Psilocybin therapy requires supervised administration. Every hour of clinician time in the protocol is a line in the cost model, and durability is the variable that makes that cost defensible. A treatment that holds for a year amortizes the session; one that does not, does not.

The funding runway. A company at a mid-teens share price needs capital to reach commercialization in a therapeutic area with no established reimbursement pathway. Positive long-term data is exactly the kind of catalyst that companies use to access the market, and equity issuance after a data pop is common enough that holders should price it as a possibility rather than a surprise. Solstice's $225 million is evidence that the capital exists for stories investors believe.

The read-across. If COMP360's durability holds up under scrutiny, it lifts the credibility of the whole supervised-psychedelic category, including private developers who will now be pointing at Compass's twelve-month curve in their own fundraising decks.

All prices cited are intraday as of the last trade at 16:29 GMT on Sept. 9, 2026, and the market was still open.

Key facts

CMPS price: 14.88, +5.98% on the day, as of 16:29 GMT Sept. 9, 2026
Compass data: Positive one-year results for psilocybin candidate COMP360
Solstice debut: $225 million
Biggest mover in the group: IRD at 5.64, +29.95%, off an intraday high of 7.08

Frequently asked questions

What did Compass Pathways report?

Compass Pathways said it posted positive data at the one-year mark for COMP360, its synthetic psilocybin candidate. The company is presenting the results as evidence that the treatment effect is durable over twelve months. Specific efficacy figures were not detailed in the disclosure summarized here, so the individual response and relapse numbers are not stated.

How did CMPS shares react?

CMPS traded at 14.88 as of the last trade at 16:29 GMT on Sept. 9, 2026, up 5.98% from a prior close of 14.04. The stock ranged from 14.05 to 15.35 during the session, meaning it gave back part of an earlier gain. The broad market was lower on the same day.

Why does one-year data matter more than short-term results in psychedelic medicine?

Short-term psilocybin results have repeatedly looked strong a few weeks after a single supervised dose. The open question has been durability: whether the effect holds, how often patients relapse, and whether repeat dosing is needed. Twelve-month data speaks to that, which affects how payers model cost per patient and how clinics plan capacity.

What was Solstice's debut worth?

Solstice made a $225 million debut. A raise of that size signals that institutional investors are willing to fund newly public biotech at scale, which is a meaningful data point for private companies weighing whether to proceed with a listing or continue waiting for better conditions.

How did the other biotech names in the same news cycle trade?

Schrodinger (SDGR) was at 19.39, down 3.20%; Assembly Biosciences (ASMB) at 33.54, down 4.93%; and Gilead (GILD) at 145.78, down 0.59%. IRD was the outlier at 5.64, up 29.95% after reaching 7.08 intraday. All figures are as of 16:29 GMT on Sept. 9, 2026.

What should investors watch next on COMP360?

Three things: how regulators weigh long-term follow-up against pivotal endpoints; whether the supervised-administration cost model is defensible if durability holds; and whether Compass uses the positive data as an opportunity to raise capital. Equity issuance following a favorable data readout is common in the sector and should be treated as a live possibility.

Sources

Compass posts positive psilocybin data; Solstice makes $225M debut — Endpoints News

Photo: https://kaboompics.com/ · Pexels Licence — source